CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

ANDA 62-756 / S-013

***Name*:** Primaxin® ADD-Vantage®
(Imipenem-Cilastatin Sodium for Injection)

***Sponsor*:** Merck Research Laboratories

***Approval Date*:** February 18, 1992

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA 62-756 / S-013

CONTENTS

Reviews / Information Included in this Review	
Approval Letter	X
Tentative Approval Letter	
Labeling	
Labeling Reviews	
Medical Review(s)	
Chemistry Review	X
Bioequivalence Review(s)	
Statistical Review(s)	
Microbiology Review	
Administrative Documents	
Correspondence	X

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA 62-756 / S-013

APPROVAL LETTER

AADA 62-756/S-013

Merck Sharp & Dohme Research Laboratories
Attn: Ronald A. Salerno, Ph.D.
Associate Director
Regulatory Liason
Sumneytown Pike
West Point, PA 19486

FEB 18 1992

Dear Sir:

Reference is made to your supplemental antibiotic drug application submitted pursuant to Section 314.70 of the Regulations, dated August 19, 1991, regarding your abbreviated antibiotic application for Primaxin® ADD-Vantage® (Imipenem-Cilastatin Sodium for Injection, MSD)

The supplemental application provides for reducing intentional overage for Sterile Imipenem and Sterile Cilastatin Sodium drug substances to —%.

We have completed the review of this supplemental application and it is approved. Our letter of January 8, 1987 detailed the conditions relating to the approval of this abbreviated application.

The material submitted is being retained as part of your application.

Sincerely yours,

Michael G. Beatrice 2/16/92

Michael G. Beatrice
Director
Division of Chemistry II
Office of Generic Drugs
Center for Drug Evaluation and Research

cc: AADA # 62-756/S-013
DUP/Division File
HFD-600/RF
HFC-130/JAllen
HFD-635/JHarrison/EDuffy/ EDuffy 12/14/92
HFD-635/MAnderson Mark Anderson 2/14/92
R/D initialed by JHarrison JHarrison 12/14/92
mw/2/14/92/62756s.013
F/T by mw/2/14/92
SUPPLEMENT APPROVAL

APPEARS THIS WAY
ON ORIGINAL

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA 62-756 / S-013

CHEMISTRY REVIEW

AADA 62-756/S-013

NAME AND ADDRESS OF APPLICANT:

Merck Sharp & Dohme Research Laboratories
Attn: Ronald A. Salerno, Ph.D.
Associate Director
Regulatory Liason
Sumneytown Pike
West Point, PA 19486

Contact:
Ronald A. Salerno, Ph.D.
Associate Director
Regulatory Liason
(215) 834-2958
or
Kenneth R. Brown, M.D.
(215) 834-2552

PURPOSE OF AMENDMENT/SUPPLEMENT
The supplemental application provides for reducing intentional overage for Sterile Imipenem and Sterile Cilastatin Sodium drug substances to —%.

DATE OF SUBMISSION
August 19, 1991

PHARMACOLOGICAL CATEGORY
Antibiotic

TRADE NAME
Primaxin® I.V. ADD-Vantage®

NONPROPRIETARY NAME
Imipenem-Cilastatin Sodium

DOSAGE FORM
Powder for reconstitution

POTENCY
250, 500 mg

RX OR OTC
℞

SAMPLES	RELATED IND/NDA/DMF
N/A	50-587 Primaxin® IV
	50-630 Primaxin® IM

STERILIZATION
N/A

LABELING
N/A

BIOEQUIVALENCY STATUS
N/A

ESTABLISHMENT INSPECTION
N/A

COMPONENTS, COMPOSITION, MANUFACTURING

APPROVED COMPOSITION

COMPONENT	250/250	500/500
STERILE IMIPENEM MONOHYDRATE	—— mg *	——mg *
STERILE CILASTATIN SODIUM	—— mg *	—— mg *
STERILE SODIUM BICARBONATE	—— mg	— mg
	—— mg	—— mg

* equivalent to 250 mg and —% overage for Imipenem & Cilastatin
* equivalent to 500 mg and —% overage for Imipenem & Cilastatin

PROPOSED COMPOSITION

COMPONENT	250/250	500/500
STERILE IMIPENEM MONOHYDRATE	—— mg *	—— mg *
STERILE CILASTATIN SODIUM	—— mg *	—— mg *
STERILE SODIUM BICARBONATE	10 mg	— mg
	—— mg	—— mg

* equivalent to 250 mg and ——% overage for Imipenem & Cilastatin
* equivalent to 500 mg and ——% overage for Imipenem & Cilastatin

CONTROLS
N/A

PACKAGING

N/A

STABILITY
Stability data indicate that each component has acceptable stability - e.g. data reported in annual report of 1/90.

REMARKS AND CONCLUSION
The proposed reduction of intentional overage from —% to ——% for Sterile Imipenem and Sterile Cilastatin Sodium drug substances is based upon statistical analysis of —— lots of drug substance produced in 1990. The drug substance assay values for both components were ——————————————————————————————.

Reducing the intentional overage to — % will serve to bring the assays closer to — .

RECOMMENDATION - APPROVABLE

RECOMMENDATION - APPROVABLE

RECALLS	Reviewer	Date Completed
	Eric P. Duffy	

cc: AADA # 62-756/S-013
Review Chemist's name: Eric P. Duffy EDuffy 2/14/92
Supervisor's name: John D. Harrison JDHarrison 2/14/92

The application covered by this review was taken in date order of receipt.

YES ✓ NO ___

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA 62-756 / S-013

CORRESPONDENCE

Vol. 3.1

MERCK SHARP & DOHME RESEARCH LABORATORIES
DIVISION OF MERCK & CO., INC.
WEST POINT, PENNSYLVANIA 19486

RONALD A. SALERNO, PH.D.
ASSOCIATE DIRECTOR
REGULATORY AFFAIRS

(215) 834-2958
(215) 661-5000
FAX (215) 834-2962

August 19, 1991

NDA NO. _____ REF. NO. SC-013
NDA SUPPL FOR Control Division

Mr. John D. Harrison, Chief
Antibiotic Drug Review Branch
HFD-635, Room 17B-31
Division of Generic Drugs
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Dear Mr. Harrison:

Supplemental New Drug Application
ANDA 62-756: Primaxin® I.V. ADD-Vantage®
(Imipenem-Cilastin Sodium for Injection, MSD)

Cross-Referenced Supplement
NDA 50-587: PRIMAXIN® I.V.
(Imipenem-Cilastatin Sodium for Injection, MSD)

Pursuant to Section 505(b) of the Food, Drug and Cosmetic Act and in accordance with 21 CFR 314.50 and 21 CFR 314.70(b), we submit for your approval, a supplement to ANDA 62-756.

As indicated in the attached Form 356h, the supplemental application provides for changes in Item 3 of the approved New Drug Application for Primaxin® I.V. ADD-Vantage®.

This supplemental application provides for the reduction of overage required for possible losses during the expiry from —% to —% for both Imipenem and Cilastatin Sodium. This reduction is based on the review of ——— stability and ——————————— data. Attachment I provides a statistical summary for —— lots which contain the —% overage.

To facilitate your review, annotated and clean copies of the page describing the ——— composition are attached.

Please note that an identical supplement is also being submitted, under separate cover, to the Primaxin® I.V. (NDA 50-587) filed with the Anti-Infective Drug Products.

ORIGINAL

We consider the filing of this Supplemental New Drug Application to be a confidential matter, and request the Food and Drug Administration not to make its content, nor any future communications in regard to it public without first obtaining the written permission of Merck & Co., Inc.

Questions concerning this supplemental application should be directed to Dr. Ronald A. Salerno (215/834-2958) or, in my absence, to Kenneth R. Brown, M.D. (215/834-2552).

Sincerely yours,

Ronald A. Salerno, Ph.D.
Associate Director
Regulatory Affairs

ALS/cat
75H

Attachments

Certified No. P 856 788 916